

> Risk factors (globally, 3rd leading cause of cancer death, espec. in Africa & Asia)


# HEPATOCELLULAR CARCINOMA (HCC)

Risk factors (globally, 3rd leading cause of cancer death, espec. in Africa & Asia)

• **Cirrhosis:** present in 70–90% HCC cases

• **Infectious:** HCV & HBV (~75%), HBV/HDV coinfection; HBV can cause HCC without cirrhosis

• **Toxic:** EtOH (⅓ cases in U.S.), tobacco, aflatoxin from Aspergillus

• **Metabolic disorders:** NASH, DM, autoimmune hepatitis, hemochromatosis

Screening (screen 病人 with cirrhosis, chronic HBV or HCV infection)

• **Ultrasonography** (U/S) + AFP q 6 mos; if high-risk may alternate U/S with **MRI**

• If lesion found or increasing AFP, perform **3-phase contrast CT or MRI**

Diagnosis

• At least **3-phase contrast-enhanced CT** or **MRI**; no biopsy or PET required for HCC dx

• Of note, only 15% of liver masses are HCC; metastatic dis. from other 1° more common

臨床表現

• Exam: nonspecific, c/w liver dysfxn (eg, hepatomegaly, ascites, jaundice, encephalopathy)

• Labs: as above, c/w liver dysfunction (eg, coagulopathy, low albumin, elevated LFTs)

治療 (_NEJM_ 2019;380:1450)

• If localized disease, goal is cure

**Resection:** typically ablation of HCC; surgery generally only considered for solitary lesions in 病人 with preserved liver fxn & adequate postop liver volume

**Liver transplant:** 1 lesion ≤5 cm or 3 lesions ≤3 cm, no vasc invasion or mets

• Palliative

### Transarterial embolization (TAE), ± chemo (TACE) or radioembolization

**Systemic therapy:** kinase inhibitors (lenvatinib, sorafenib), PD-1 inhib (nivolumab) ä OS in advanced HCC (_Lancet_ 2017;389:2492 & 2018;391:1163)
